Pub. Date : 2012 Sep
PMID : 22871995
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow therapeutic index and highly variable pharmacokinetics. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | In vivo CYP3A4 activity and CYP3A5 genotype explain 56-59% of variability in tacrolimus dose requirements and clearance, contributing ~25 and 30%, respectively. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |